Form 4: Janux CTO Winter Reports Stock Transactions

Janux Therapeutics' Chief Technical Officer, Charles M. Winter, reported the sale of shares for tax obligations and the acquisition of new restricted stock units and stock options.

Summary

• Charles M. Winter, Chief Technical Officer of Janux Therapeutics, Inc. (JANX), reported several transactions on January 2, 2026.
• Sold 2,401 shares of common stock at a price of $13.73 per share to cover tax withholding obligations associated with the vesting of restricted stock units.
• Received a grant of 28,600 Restricted Stock Units (RSUs) at a price of $0, with vesting scheduled in four equal annual installments beginning on January 1, 2027.
• Received a grant of 100,100 stock options with an exercise price of $13.65, where 25% will vest on January 1, 2027, and the remainder will vest in equal monthly installments over a three-year period.
• Beneficially owns 106,321 shares of common stock and 100,100 stock options following these reported transactions.
• Previously acquired 2,834 shares under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2025.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation, with significant grants of RSUs and stock options, which are generally positive for aligning management incentives. The sale of shares was for tax purposes, not a discretionary divestment, making the overall sentiment neutral to positive.

Positives

• Grant of 28,600 Restricted Stock Units (RSUs) at $0, representing future equity ownership and aligning executive interests with company performance.
• Grant of 100,100 stock options with an exercise price of $13.65, providing potential future upside tied to stock appreciation.
• Inclusion of 2,834 shares acquired under the Employee Stock Purchase Plan on May 15, 2025, indicating ongoing executive investment in the company.

Negatives

• Sale of 2,401 shares of common stock at $13.73, though this was explicitly for tax withholding obligations and not a discretionary divestment.

Future Outlook

The grants of Restricted Stock Units and stock options indicate a long-term incentive structure for the Chief Technical Officer, with vesting schedules extending through January 2027 and beyond, aligning management's interests with future company performance.

Industry Context

These transactions represent routine equity compensation and tax-related sales for a key executive in the biotechnology or pharmaceutical industry, common practice for retaining talent and aligning executive incentives with shareholder value.

Stakeholder Impact

• Shareholders: The grants of equity awards to a key executive like the CTO can align management's long-term interests with shareholder value, potentially fostering sustained growth.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates a broader program for employee equity participation, which can boost morale and retention.

Next Steps

• Vesting of 25% of stock options on January 1, 2027, with the remainder vesting monthly over three years.
• Vesting of Restricted Stock Units in four equal annual installments beginning January 1, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation, including grants of restricted stock units and stock options, and a tax-related sale of shares. While the grants are positive for executive alignment, these transactions do not provide new fundamental information about Janux Therapeutics' operational performance or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals rather than these specific insider transactions.

Keywords

Janux Therapeutics, JANX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Charles M. Winter, CTO, SEC Filing